Home › Companies › KalVista Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and KalVista Pharmaceuticals, Inc.’s Form 8-K, filed 2025-10-02 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore KalVista Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are KalVista Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-10-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Benjamin L. Palleiko | 36,096,804 | 1,491,876 | 3,100 | -- | 3,882,274 | Majority: yes |
| Elect Director: Brian J.G. Pereira | 30,303,728 | 7,284,941 | 3,111 | -- | 3,882,274 | Majority: yes |
| Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the eight-month transition period ending December 31, 2025: | 41,421,548 | 44,417 | 8,089 | -- | 0 | Majority: yes |
| Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers: | 33,600,808 | 3,985,860 | 5,112 | -- | 3,882,274 | Majority: yes |
Source: KalVista Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-10-02 — read the filing on EDGAR.
Each item below shows how the 168 asset managers that disclosed a KalVista Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
KalVista Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:”): 33,600,808 for, 3,985,860 against, per its Form 8-K filed 2025-10-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 78% for, 9% against (87% of the company cast a for/against vote).
The 165 asset managers below cast 80% of the shares they voted on this item FOR (26,700,240 for, 6,567,124 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 6,728,985 | 0 | 0 | 0 | For |
| Capital Group | 0 | 6,355,174 | 0 | 0 | Against |
| MONTANOVA CAPITAL, LLC | 4,768,712 | 0 | 0 | 0 | For |
| BlackRock | 2,302,322 | 20,039 | 0 | 0 | For |
| Vanguard | 2,219,051 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,296,235 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 1,068,496 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 951,112 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 888,355 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 601,685 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 505,438 | 0 | 0 | 0 | For |
| State Street | 465,633 | 121 | 0 | 0 | For |
| DAFNA Capital Management LLC | 444,731 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 353,425 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 340,145 | 0 | 0 | 0 | For |
| Fidelity | 322,713 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 316,095 | 0 | 0 | 0 | For |
| Principal | 288,361 | 0 | 0 | 0 | For |
| Northern Trust | 256,985 | 0 | 0 | 0 | For |
| Charles Schwab | 226,985 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 3,490 | 0 | 0 | For |
| NAN FUNG TRINITY (HK) Ltd | 154,522 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 149,507 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 113,171 | 0 | 0 | 0 | For |
| Russell Investments | 105,878 | 0 | 0 | 0 | For |
Showing the 25 largest of 165 asset managers. See all 165 in the interactive database.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Benjamin L. Palleiko”): 36,096,804 for, 1,491,876 against, per its Form 8-K filed 2025-10-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 84% for, 3% against (87% of the company cast a for/against vote).
The 42 asset managers below cast 89% of the shares they voted on this item FOR (7,651,957 for, 905,786 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 3,177,587 | 0 | 0 | 0 | For |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 601,685 | 0 | 0 | Against |
| Principal | 1,691 | 286,670 | 0 | 0 | Against |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 95,008 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 78,858 | 0 | 0 | 0 | For |
| TIAA | 67,977 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 52,939 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 50,205 | 0 | 0 | 0 | For |
| State Street | 41,676 | 0 | 0 | 0 | For |
| Northern Trust | 30,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 29,200 | 0 | 0 | 0 | For |
| ProShares | 19,863 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,236 | 0 | 0 | 0 | For |
| Global X | 19,029 | 0 | 0 | 0 | For |
| Dimensional | 0 | 17,431 | 0 | 0 | Against |
| John Hancock | 14,574 | 0 | 0 | 0 | For |
| Invesco | 14,068 | 0 | 0 | 0 | For |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 4 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brian J.G. Pereira”): 30,303,728 for, 7,284,941 against, per its Form 8-K filed 2025-10-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 70% for, 17% against (87% of the company cast a for/against vote).
The 42 asset managers below cast 83% of the shares they voted on this item FOR (7,136,671 for, 1,421,072 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 3,177,587 | 0 | 0 | 0 | For |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 601,685 | 0 | 0 | Against |
| Principal | 0 | 288,361 | 0 | 0 | Against |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 68,398 | 26,610 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 78,858 | 0 | 0 | Against |
| TIAA | 0 | 67,977 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 52,939 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 50,205 | 0 | 0 | Against |
| State Street | 67 | 41,609 | 0 | 0 | Against |
| Northern Trust | 0 | 30,794 | 0 | 0 | Against |
| Lincoln Financial | 0 | 29,200 | 0 | 0 | Against |
| ProShares | 0 | 19,863 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 19,236 | 0 | 0 | Against |
| Global X | 0 | 19,029 | 0 | 0 | Against |
| Dimensional | 0 | 17,431 | 0 | 0 | Against |
| John Hancock | 0 | 14,574 | 0 | 0 | Against |
| Invesco | 0 | 14,068 | 0 | 0 | Against |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
KalVista Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the eight-month transition period ending December 31, 2025:”): 41,421,548 for, 44,417 against, per its Form 8-K filed 2025-10-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 96% for, 0.2% against (96% of the company cast a for/against vote).
The 42 asset managers below cast 99.9% of the shares they voted on this item FOR (8,557,741 for, 2 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 3,177,587 | 0 | 0 | 0 | For |
| Vanguard | 2,116,269 | 0 | 0 | 0 | For |
| BlackRock | 1,071,698 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 601,685 | 0 | 0 | 0 | For |
| Principal | 288,361 | 0 | 0 | 0 | For |
| Fidelity | 275,464 | 0 | 0 | 0 | For |
| BNY Mellon | 215,842 | 0 | 0 | 0 | For |
| Charles Schwab | 113,454 | 0 | 0 | 0 | For |
| Equitable | 95,008 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 78,858 | 0 | 0 | 0 | For |
| TIAA | 67,977 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,500 | 0 | 0 | 0 | For |
| Russell Investments | 52,939 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 50,205 | 0 | 0 | 0 | For |
| State Street | 41,674 | 2 | 0 | 0 | For |
| Northern Trust | 30,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 29,200 | 0 | 0 | 0 | For |
| ProShares | 19,863 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,236 | 0 | 0 | 0 | For |
| Global X | 19,029 | 0 | 0 | 0 | For |
| Dimensional | 17,431 | 0 | 0 | 0 | For |
| John Hancock | 14,574 | 0 | 0 | 0 | For |
| Invesco | 14,068 | 0 | 0 | 0 | For |
| Pacific Life | 11,918 | 0 | 0 | 0 | For |
| Nationwide | 11,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Ranked by the number of KalVista Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 43,215,472 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Venrock Adviser, LLC | 15.57% |
| 2 | Capital Group | 14.71% |
| 3 | MONTANOVA CAPITAL, LLC | 11.03% |
| 4 | BlackRock | 5.37% |
| 5 | Vanguard | 5.13% |
| 6 | Vestal Point Capital, LP | 3.00% |
| 7 | Octagon Capital Advisors LP | 2.47% |
| 8 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.20% |
| 9 | EMERALD MUTUAL FUND ADVISERS TRUST | 2.06% |
| 10 | RBB FUND, INC. | 1.39% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Venrock Healthcare Capital Partners III, L.P. | 11.60% | DEF14A |
| Tang Capital Partners, LP | 11.44% | DEF14A |
| Entities affiliated with Frazier Life Sciences Public Fund, L.P. | 11.31% | DEF14A |
| Entities affiliated with Suvretta Capital Management, LLC | 10.02% | DEF14A |
| Vestal Point Capital, L.P. | 9.26% | DEF14A |
| BlackRock | 8.78% | 13F |
| Capital World Investors | 7.35% | DEF14A |
| Vanguard Group | 5.81% | 13F |
| Point72 | 4.94% | 13F |
| State Street | 4.53% | 13F |
Percentages above are of 43,215,472 shares outstanding, as reported by KalVista Pharmaceuticals, Inc. on its Form 10-Q dated 2024-08-26 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KalVista Pharmaceuticals, Inc.’s 10-Q dated 2024-08-26. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At KalVista Pharmaceuticals, Inc.'s shareholder meeting held 2025-10-01, in the 2025-2026 proxy season, 168 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 636 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation paid by us to our named… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KalVista Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-10-02.
KalVista Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).